Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 134

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 134
---
 consider cross-border cooperation with securities
regulatory authority of the PRC by way of judicial assistance, diplomatic channels or regulatory cooperation mechanism established with
the securities regulatory authority of the PRC.

We have ceased to qualify as an “emerging growth company” and will incur increased costs as a result.

We ceased to be an “emerging
growth company” on December 31, 2023. Accordingly, we are no longer eligible for reduced disclosure requirements and exemptions
available to EGCs and, among other things, will formally become subject to new accounting pronouncement effective dates for non-EGCs.
While we have determined that we are neither an accelerated filer nor a large accelerated filer (as such terms are defined under U.S.
federal securities laws) and therefore not required to obtain an attestation report from our independent registered public accounting
firm on the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act, we nevertheless
expect to incur additional legal, accounting, financial and other costs associated with being a public company that is not an EGC, including
mandatory adoption of new accounting pronouncements. We may also incur costs associated with compliance with the requirements of additional
disclosure requirements, including Section 404(b) of the Sarbanes-Oxley Act in the event that we determine that we have become an accelerated
filer or large accelerated filer.

Further, investors may find
our securities less attractive because of our reliance on the foregoing exemption from Section 404(b) of the Sarbanes-Oxley Act, as well
as any other exemptions available to us under U.S. federal securities laws. This could contribute to a less active trading market for
our securities and prices of the securities may be more volatile or decline.

<div align='center'>61

RISKS RELATED TO DIAMIR’S BUSINESS AND OPERATIONS</div>

Unless otherwise stated, all references to “DiamiR,” and similar designations under this section, Risks Related to DiamiR’s Business and Operations, refer to DiamiR Biosciences Corp, a Delaware corporation, and its wholly-owned subsidiary DiamiR, LLC a private Delaware limited liability company.

DiamiR may not complete the Merger or may be delayed in completing the Merger.

The DiamiR Merger is at the
very early stages and will be subject to the completion of satisfactory due diligence, negotiation of definitive agreements, obtaining
applicable corporate, regulatory and other